Notably, no differences in outcomes between males and females have been shown for anaplastic lymphoma kinase (ALK) inhibitors in patients with NSCLC [38], or for TKIs (e.g., imatinib) used to treat patients with chronic myeloid leukemia [39, 40]. Here, ALK is linked to non-small cell lung carcinoma.